NPPA fixes price caps for 12 anti-diabetic medicines

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) on Monday said it has fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution. In a tweet, the drug price regulator said, “To make it possible for every Indian to afford medical treatment against diseases like diabetes, NPPA has initiated a successful step by fixing the ceiling prices of 12 anti-diabetic generic medicines.”

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet.

The ceiling price of 1 ml glucose injection of 25 per cent strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is Rs 15.09.

Similarly, 1 ml of intermediate acting (NPH) solution insulin injection of strength 40 IU/ml has a ceiling price of Rs 15.09, and that of 1 ml of premix insulin 30:70 injection (regular NPH) injection of strength 40 IU/ml is also Rs 15.09.

NPPA further said the ceiling price of metformin immediate release tablet of strength 500 mg has been fixed at Rs 1.51 per tablet, while that of 750 mg strength is at Rs 3.05 per tablet and 1,000 mg strength at Rs 3.61 per tablet.

For metformin control release tablet of strength 1000 mg, the ceiling price is Rs 3.66 per tablet, NPPA said, adding the same for 750 mg strength is Rs 2.4 per tablet and Rs 1.92 per tablet for metformin control release tablet of strength 500 mg.

  • Related Posts

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    During the raid, the accused were allegedly found storing medicines and pharmaceutical drugs without valid licences, permits or authorisations and replacing labels on the stored medicines. The Directorate of Enforcement…

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Hyderabad startup PopVax develops personalised cancer vaccines using AI, machine learning, and mRNA tech to target unique tumour mutations. Cancer treatment is increasingly moving towards personalised approaches that take into…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Medicines that cure Us are making Our Environment Sick

    Medicines that cure Us are making Our Environment Sick

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs